Overview

Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries

Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Magnevist (the study drug) used for MRI of the infrarenal aorta and peripheral arteries. The results will be compared to the results of MRI taken without Magnevist, and with the results of your X-ray angiography.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bayer
Criteria
Inclusion Criteria:

- Has known or suspected peripheral vascular disease

- Is scheduled for X-ray angiography

Exclusion Criteria:

- Has any contraindication to magnetic resonance imaging

- Is scheduled for any procedure before the X-ray angiography

- Had previously had stents placed bilaterally in the region to be imaged